TY - JOUR
T1 - Highlights from the 2022 ASCO gastrointestinal cancer symposium
T2 - An overview by the EORTC gastrointestinal tract cancer group
AU - Sclafani, Francesco
AU - Fontana, Elisa
AU - Wyrwicz, Lucjan
AU - Wagner, Anna Dorothea
AU - Valle, Juan W.
AU - Smyth, Elizabeth
AU - Peeters, Mark
AU - Obermannova, Radka
AU - Neuzillet, Cindy
AU - Lutz, Manfred P.
AU - Koessler, Thibaud
AU - Ben-Aharon, Irit
AU - Arnold, Dirk
AU - Alsina, Maria
AU - Moehler, Markus
N1 - Publisher Copyright:
© 2022 Elsevier Inc.
PY - 2022/9
Y1 - 2022/9
N2 - Recently, we have witnessed impressive diagnostic and therapeutic changes for gastrointestinal cancer patients. New challenges brought by the COVID-19 pandemic have led us to re-evaluate our work priorities. Thanks to the commendable resilience of both investigators and patients, however, clinical research never stopped. In addition to conducting cutting-edge research and serving patients’ needs, as EORTC Gastrointestinal Tract Cancer Group, we are committed to pursuing educational initiatives beneficial to the entire European oncology community and beyond. In this regard, we have been providing critical discussions of new data from major international meetings. In this article, we discuss results of important selected studies presented at the 2022 ASCO Gastrointestinal Cancer Symposium, putting them in perspectives and highlighting potential implications for routine practice. With the number of in-person attendees and practice-changing/informing trials presented, this meeting represented a milestone in the return to normality as well as in the fight against cancer.
AB - Recently, we have witnessed impressive diagnostic and therapeutic changes for gastrointestinal cancer patients. New challenges brought by the COVID-19 pandemic have led us to re-evaluate our work priorities. Thanks to the commendable resilience of both investigators and patients, however, clinical research never stopped. In addition to conducting cutting-edge research and serving patients’ needs, as EORTC Gastrointestinal Tract Cancer Group, we are committed to pursuing educational initiatives beneficial to the entire European oncology community and beyond. In this regard, we have been providing critical discussions of new data from major international meetings. In this article, we discuss results of important selected studies presented at the 2022 ASCO Gastrointestinal Cancer Symposium, putting them in perspectives and highlighting potential implications for routine practice. With the number of in-person attendees and practice-changing/informing trials presented, this meeting represented a milestone in the return to normality as well as in the fight against cancer.
KW - Clinical trials
KW - Colorectal cancers
KW - Esophago-gastric cancers
KW - Hepato-pancreatico-biliary cancers
KW - Meeting
UR - http://www.scopus.com/inward/record.url?scp=85130936015&partnerID=8YFLogxK
U2 - 10.1016/j.clcc.2022.04.001
DO - 10.1016/j.clcc.2022.04.001
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 35637095
AN - SCOPUS:85130936015
SN - 1533-0028
VL - 21
SP - 188
EP - 197
JO - Clinical Colorectal Cancer
JF - Clinical Colorectal Cancer
IS - 3
ER -
